A Personalised Vaccine for Ovarian Cancer: Early Results
NeoVax, personalised from each patient’s tumour, was feasible and acceptably safe with nivolumab in an early ovarian trial. A careful reading.
NeoVax, personalised from each patient’s tumour, was feasible and acceptably safe with nivolumab in an early ovarian trial. A careful reading.